Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023 ...Middle East

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic,...

Hence then, the article about innovent releases final analysis results of orient 15 the phase 3 study of sintilimab plus chemotherapy for the first line treatment of esophageal squamous cell carcinoma at the aacr annual meeting 2023 was published today ( Monday 17/04/2023 - 03:24 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023 )

Also on site :

• Walmart's 'Super Cute' Half Moon Shoulder Bag Brings the Cow Print Trend to Your Wardrobe for Just $20
• James Murdoch may have reaped as much as $7.5 billion from his pre-IPO investment in Elon Musk’s SpaceX
• Rosie O'Donnell Says Prison Visit Led to Her First Real Conversation With Daughter Chelsea in 10 Years